VI Partners AG

About The Fund

VI Partners AG is a Swiss-based venture capital firm that specializes in early-stage investments. With headquarters at Bahnhofstrasse 1, Altendorf, CH-8852, Switzerland, they focus on sectors including IT, TMT, BioTech, Hardware, Manufacturing, Material Science, Medical Devices, Hospital Services, Life Science, and Pharmaceutical. Their expertise lies in equity funding, with a minimum investment range starting from 500,000 and going up to 5 million. VI Partners takes pride in their specialities which encompass seed, startup, and early-stage company investments. Founded in 2001 to advise Venture Incubator AG, VI Partners carries a mission to stimulate entrepreneurship and nurture the venture capital industry within Switzerland. Over the past two decades, they have made 65 investments, with about two-thirds of these being ventures originating as spin-offs from ETH Zurich, EPF Lausanne, and other Swiss universities. More than half of their investments have been seed-stage ventures. Early portfolio companies include Ganymed (sold to ATS), Esbatech (sold to Alcon/Novartis), and Kuros (IPO at SWX), showcasing their success and impactful presence in the industry. Their investments in companies like Endoart, Endosense, Neocutis, Activaero, Nexthink, Amal, and SumUp illustrate their significant role in supporting startups that achieved billion-dollar valuations and attracting investments from top global venture firms. With 26 exits realized, the creation of thousands of high-value jobs, and active participation in establishing a vibrant Swiss VC ecosystem, VI Partners stands as one of the best-known VC firms in Switzerland, actively investing in ventures across Europe. The firm manages assets worth 95 million and continues to bolster entrepreneurship and the Swiss startup landscape.